Apollomics (APLMW) Competitors $0.02 +0.00 (+14.37%) As of 10/13/2025 03:30 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock APLMW vs. ATNFW, SXTPW, DRTSW, BCTXW, CDIOW, CELUW, CEROW, CINGW, CLNNW, and COEPWShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), Clene (CLNNW), and Coeptis Therapeutics (COEPW). These companies are all part of the "biotechnology" industry. Apollomics vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene Coeptis Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Apollomics (NASDAQ:APLMW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Does the media prefer ATNFW or APLMW? In the previous week, Apollomics had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for Apollomics and 0 mentions for 180 Life Sciences. Apollomics' average media sentiment score of 1.89 beat 180 Life Sciences' score of 0.00 indicating that Apollomics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Apollomics Very Positive Is ATNFW or APLMW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Apollomics N/A N/A N/A Which has stronger earnings & valuation, ATNFW or APLMW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AApollomicsN/AN/AN/AN/AN/A SummaryApollomics beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLMW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLMW vs. The Competition Export to ExcelMetricApollomicsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$225.85M$6.03B$10.43BDividend YieldN/A3.81%5.73%4.82%P/E RatioN/A99.1085.1426.98Price / SalesN/A5,788.72593.69130.89Price / CashN/A13.1925.7730.18Price / BookN/A100.2912.336.67Net IncomeN/A-$90.99M$3.32B$276.55M7 Day PerformanceN/A-0.16%-0.38%-0.42%1 Month PerformanceN/A4.60%8.34%6.58%1 Year PerformanceN/A675.16%73.00%40.76% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMWApollomicsN/A$0.02+14.4%N/AN/A$0.00N/A0.0059News CoveragePositive NewsGap DownHigh Trading VolumeATNFW180 Life SciencesN/A$0.08+33.6%N/A+523.3%$0.00N/A0.007SXTPW60 Degrees PharmaceuticalsN/A$0.05+8.5%N/A+326.7%$0.00$641.41K0.002Gap UpDRTSWAlpha Tau MedicalN/A$0.40+9.0%N/AN/A$0.00N/A0.0080Positive NewsGap DownBCTXWBriaCell TherapeuticsN/A$0.04+20.6%N/A-84.6%$0.00N/A0.008News CoverageCDIOWCardio DiagnosticsN/A$0.02+9.0%N/A-50.0%$0.00$19.51K0.007Positive NewsGap DownHigh Trading VolumeCELUWCelularityN/A$0.04-7.4%N/AN/A$0.00$44.59M0.00220Gap DownCEROWCERo TherapeuticsN/A$0.02+7.6%N/A+157.1%$0.00N/A0.008Positive NewsCINGWCingulateN/A$0.05+16.6%N/A-3.4%$0.00N/A0.0020Positive NewsCLNNWCleneN/A$0.02-34.2%N/A-64.2%$0.00$286K0.00100Positive NewsGap UpHigh Trading VolumeCOEPWCoeptis TherapeuticsN/A$0.03+3.7%N/A+37.4%$0.00$263.56K0.004Gap Down Related Companies and Tools Related Companies ATNFW Alternatives SXTPW Alternatives DRTSW Alternatives BCTXW Alternatives CDIOW Alternatives CELUW Alternatives CEROW Alternatives CINGW Alternatives CLNNW Alternatives COEPW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLMW) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
